Research programme: muscular dystrophy therapeutics - Prothelia/University of Nevada
Alternative Names: Laminin-111; PRT-01; PRT-300; PRT-400; PRT-500Latest Information Update: 28 Mar 2018
At a glance
- Originator University of Nevada Reno
- Developer Prothelia; University of Nevada Reno
- Class Proteins; Small molecules
- Mechanism of Action Integrin modulators; Protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Limb girdle muscular dystrophies; Muscular dystrophies
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
- 28 Mar 2018 No recent reports of development identified for preclinical development in Limb-girdle-muscular-dystrophies in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA